慢性腰痛生物学治疗的研究进展
王峣
徐志杰
李海昕
姚家骐
1.海军军医大学学员旅、海军军医大学药学院、海军军医大学医学系, 上海,2004332.海军军医大学学员旅、海军军医大学药学院、海军军医大学医学系, 上海,2004333.海军军医大学学员旅、海军军医大学药学院、海军军医大学医学系, 上海,2004334.海军军医大学学员旅、海军军医大学药学院、海军军医大学医学系, 上海,200433
摘要：Current therapies for chronic low back pain include conservative therapy, biological therapy and surgical therapy, yet the therapeutic options are very limited before the surgery. Meanwhile, it is rare to see the biological therapy in China. Based on the pathogenesis of the low back pain, this article reviews some foreign literatures in recent years, introducing the chemonucleolysis by chymopapain as the first drug in an intradiscal injection to reduce herniated disc size and other new medications such as chondroitinase, matrix metalloproteinases, and ethanol gel. This article also introduces a minimally invasive intravenous glial cell-derived neurotrophic growth factor named artemin, a subcutaneous monoclonal antibody acting as nerve growth factor named tanezumab for low back pain without radiculopathy, as well as the biological culture of intervertebral disc. The author aims at enriching the option of therapies between conservative therapy and surgical therapy, and reducing the adverse effects.
关键词：腰痛慢性疼痛治疗学综述
分类号：R681.5(骨科学（运动系疾病、矫形外科学）)
资助基金：海军军医大学"大学生创新能力培养"基金项目(MS2016039)
论文发表日期：2018-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：5( 449-453 )
英文信息